Nestlé Acquires Peanut Allergy Treatment Maker, Aimmune Therapeutics

By: Gyarmati Orsolya Date: 2020. 10. 15. 08:10

Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia.

Aimmune Therapeutics will be a part of Nestlé Health Science (NHSc) as a stand-alone business unit and continue to operate from Brisbane, California.

In August of this year, Nestlé offered $2 billion (€1.7 billion) to gain full ownership of the California-based biopharmaceutical company.


Related news